Reading the paper to be published this weekend in the International Pharmaceutical Journal would make one wonder whether Aztrezenica has big plans for a Nanotechnology division. As Captain Barnacles pointed out this paper is all about testing,quality control and consistency of DEP drugs these drugs as he states probably near impossible for generic producers to replicate to approval level. When AZD4066 moves through to market I ask the question could Aztrezenica be considering making this a much larger part of their company. After all they have another two drugs under current Starpharma licence and another one of their own drugs in Starpharma lab on foot. With three drugs finishing phase 2 and ability and team to bring more forward as required could be a very good move forward for Aztrezenica, a range of newly patented, hard to copy effective drugs with little side effects and uncompromised efficacy. Only my thoughts welcome any constructive comments.
SPL Price at posting:
49.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)